259 related articles for article (PubMed ID: 16947019)
1. T cell responses in melanoma patients after vaccination with tumor-mRNA transfected dendritic cells.
Kyte JA; Kvalheim G; Lislerud K; thor Straten P; Dueland S; Aamdal S; Gaudernack G
Cancer Immunol Immunother; 2007 May; 56(5):659-75. PubMed ID: 16947019
[TBL] [Abstract][Full Text] [Related]
2. Preclinical full-scale evaluation of dendritic cells transfected with autologous tumor-mRNA for melanoma vaccination.
Kyte JA; Kvalheim G; Aamdal S; Saebøe-Larssen S; Gaudernack G
Cancer Gene Ther; 2005 Jun; 12(6):579-91. PubMed ID: 15818380
[TBL] [Abstract][Full Text] [Related]
3. Phase I/II trial of melanoma therapy with dendritic cells transfected with autologous tumor-mRNA.
Kyte JA; Mu L; Aamdal S; Kvalheim G; Dueland S; Hauser M; Gullestad HP; Ryder T; Lislerud K; Hammerstad H; Gaudernack G
Cancer Gene Ther; 2006 Oct; 13(10):905-18. PubMed ID: 16710345
[TBL] [Abstract][Full Text] [Related]
4. Immuno-gene therapy of cancer with tumour-mRNA transfected dendritic cells.
Kyte JA; Gaudernack G
Cancer Immunol Immunother; 2006 Nov; 55(11):1432-42. PubMed ID: 16612595
[TBL] [Abstract][Full Text] [Related]
5. Increased non-major histocompatibility complex-restricted lytic activity in melanoma patients vaccinated with cytokine gene-transfected autologous tumor cells.
Möller P; Möller H; Sun Y; Dorbic T; Henz BM; Wittig B; Schadendorf D
Cancer Gene Ther; 2000 Jul; 7(7):976-84. PubMed ID: 10917199
[TBL] [Abstract][Full Text] [Related]
6. Dendritic cells loaded with killed allogeneic melanoma cells can induce objective clinical responses and MART-1 specific CD8+ T-cell immunity.
Palucka AK; Ueno H; Connolly J; Kerneis-Norvell F; Blanck JP; Johnston DA; Fay J; Banchereau J
J Immunother; 2006; 29(5):545-57. PubMed ID: 16971810
[TBL] [Abstract][Full Text] [Related]
7. Enzyme-linked immunospot, cytokine flow cytometry, and tetramers in the detection of T-cell responses to a dendritic cell-based multipeptide vaccine in patients with melanoma.
Whiteside TL; Zhao Y; Tsukishiro T; Elder EM; Gooding W; Baar J
Clin Cancer Res; 2003 Feb; 9(2):641-9. PubMed ID: 12576430
[TBL] [Abstract][Full Text] [Related]
8. Preclinical evaluation of autologous dendritic cells transfected with mRNA or loaded with apoptotic cells for immunotherapy of high-risk neuroblastoma.
Jarnjak-Jankovic S; Pettersen RD; Saebøe-Larssen S; Wesenberg F; Olafsen MR; Gaudernack G
Cancer Gene Ther; 2005 Aug; 12(8):699-707. PubMed ID: 15846368
[TBL] [Abstract][Full Text] [Related]
9. A phase-I trial using a universal GM-CSF-producing and CD40L-expressing bystander cell line (GM.CD40L) in the formulation of autologous tumor cell-based vaccines for cancer patients with stage IV disease.
Dessureault S; Noyes D; Lee D; Dunn M; Janssen W; Cantor A; Sotomayor E; Messina J; Antonia SJ
Ann Surg Oncol; 2007 Feb; 14(2):869-84. PubMed ID: 17103257
[TBL] [Abstract][Full Text] [Related]
10. A pilot clinical trial of vaccination with dendritic cells pulsed with autologous tumor cells derived from malignant pleural effusion in patients with late-stage lung carcinoma.
Chang GC; Lan HC; Juang SH; Wu YC; Lee HC; Hung YM; Yang HY; Whang-Peng J; Liu KJ
Cancer; 2005 Feb; 103(4):763-71. PubMed ID: 15637694
[TBL] [Abstract][Full Text] [Related]
11. Boosting T cell-mediated immunity to tyrosinase by vaccinia virus-transduced, CD34(+)-derived dendritic cell vaccination: a phase I trial in metastatic melanoma.
Di Nicola M; Carlo-Stella C; Mortarini R; Baldassari P; Guidetti A; Gallino GF; Del Vecchio M; Ravagnani F; Magni M; Chaplin P; Cascinelli N; Parmiani G; Gianni AM; Anichini A
Clin Cancer Res; 2004 Aug; 10(16):5381-90. PubMed ID: 15328176
[TBL] [Abstract][Full Text] [Related]
12. alpha-fetoprotein and interleukin-18 gene-modified dendritic cells effectively stimulate specific type-1 CD4- and CD8-mediated T-Cell response from hepatocellular carcinoma patients in Vitro.
Cao DY; Yang JY; Dou KF; Ma LY; Teng ZH
Hum Immunol; 2007 May; 68(5):334-41. PubMed ID: 17462500
[TBL] [Abstract][Full Text] [Related]
13. Human dendritic cells genetically engineered to express a melanoma polyepitope DNA vaccine induce multiple cytotoxic T-cell responses.
Smith SG; Patel PM; Porte J; Selby PJ; Jackson AM
Clin Cancer Res; 2001 Dec; 7(12):4253-61. PubMed ID: 11751527
[TBL] [Abstract][Full Text] [Related]
14. Blood dendritic cells generated with Flt3 ligand and CD40 ligand prime CD8+ T cells efficiently in cancer patients.
Davis ID; Chen Q; Morris L; Quirk J; Stanley M; Tavarnesi ML; Parente P; Cavicchiolo T; Hopkins W; Jackson H; Dimopoulos N; Tai TY; MacGregor D; Browning J; Svobodova S; Caron D; Maraskovsky E; Old LJ; Chen W; Cebon J
J Immunother; 2006; 29(5):499-511. PubMed ID: 16971806
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of dendritic cells loaded with apoptotic cancer cells or expressing tumour mRNA as potential cancer vaccines against leukemia.
Jarnjak-Jankovic S; Pettersen RD; Saebøe-Larssen S; Wesenberg F; Gaudernack G
BMC Cancer; 2005 Feb; 5():20. PubMed ID: 15720715
[TBL] [Abstract][Full Text] [Related]
16. Vaccination of melanoma patients using dendritic cells loaded with an allogeneic tumor cell lysate.
Salcedo M; Bercovici N; Taylor R; Vereecken P; Massicard S; Duriau D; Vernel-Pauillac F; Boyer A; Baron-Bodo V; Mallard E; Bartholeyns J; Goxe B; Latour N; Leroy S; Prigent D; Martiat P; Sales F; Laporte M; Bruyns C; Romet-Lemonne JL; Abastado JP; Lehmann F; Velu T
Cancer Immunol Immunother; 2006 Jul; 55(7):819-29. PubMed ID: 16187085
[TBL] [Abstract][Full Text] [Related]
17. A phase I vaccination study with tyrosinase in patients with stage II melanoma using recombinant modified vaccinia virus Ankara (MVA-hTyr).
Meyer RG; Britten CM; Siepmann U; Petzold B; Sagban TA; Lehr HA; Weigle B; Schmitz M; Mateo L; Schmidt B; Bernhard H; Jakob T; Hein R; Schuler G; Schuler-Thurner B; Wagner SN; Drexler I; Sutter G; Arndtz N; Chaplin P; Metz J; Enk A; Huber C; Wölfel T
Cancer Immunol Immunother; 2005 May; 54(5):453-67. PubMed ID: 15627214
[TBL] [Abstract][Full Text] [Related]
18. A phase II trial of vaccination with autologous, tumor-derived heat-shock protein peptide complexes Gp96, in combination with GM-CSF and interferon-alpha in metastatic melanoma patients.
Pilla L; Patuzzo R; Rivoltini L; Maio M; Pennacchioli E; Lamaj E; Maurichi A; Massarut S; Marchianò A; Santantonio C; Tosi D; Arienti F; Cova A; Sovena G; Piris A; Nonaka D; Bersani I; Di Florio A; Luigi M; Srivastava PK; Hoos A; Santinami M; Parmiani G
Cancer Immunol Immunother; 2006 Aug; 55(8):958-68. PubMed ID: 16215718
[TBL] [Abstract][Full Text] [Related]
19. Comparative analysis of DC fused with tumor cells or transfected with tumor total RNA as potential cancer vaccines against hepatocellular carcinoma.
Zhang HM; Zhang LW; Liu WC; Cheng J; Si XM; Ren J
Cytotherapy; 2006; 8(6):580-8. PubMed ID: 17148035
[TBL] [Abstract][Full Text] [Related]
20. Dendritoma vaccination combined with low dose interleukin-2 in metastatic melanoma patients induced immunological and clinical responses.
Wei Y; Sticca RP; Holmes LM; Burgin KE; Li J; Williamson J; Evans L; Smith SJ; Stephenson JJ; Wagner TE
Int J Oncol; 2006 Mar; 28(3):585-93. PubMed ID: 16465362
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]